7.2.5.5	  Summary of evidence and recommendations for neoadjuvant and adjuvant therapy,
Recommendations,Strength rating
Discuss the contradictory results of the available adjuvant ICI trials with patients to facilitate   shared decision making.,Strong
Inform patients about the potential risk of overtreatment and immune-related side effects if   adjuvant therapy is considered.,Strong
"Do not offer adjuvant therapy with sorafenib, pazopanib, everolimus, girentuximab, or   axitinib.",Strong
Do not offer adjuvant sunitinib following surgically resected high-risk clear-cell renal cell   carcinoma (ccRCC).,Weak
"Offer adjuvant pembrolizumab to ccRCC patients, preferably within 12–16 weeks post-  nephrectomy, with a recurrence risk as defined in the Keynote-564 trial:  •   Intermediate-high risk:   •   pT2, grade 4 or sarcomatoid, N0, M0  •   pT3, any grade, N0, M0  •   High risk:  •   pT4, any grade, N0, M0  •   any pT, any grade, N+, M0  •   M1 no evidence of disease (NED):  •   NED after resection of oligometastatic sites < 1 year from nephrectomy",Weak
